vs
Apellis Pharmaceuticals, Inc.（APLS）与Pebblebrook Hotel Trust（PEB）财务数据对比。点击上方公司名可切换其他公司
Pebblebrook Hotel Trust的季度营收约是Apellis Pharmaceuticals, Inc.的1.7倍（$345.7M vs $199.9M），Pebblebrook Hotel Trust净利率更高（-5.3% vs -29.5%，领先24.2%），Pebblebrook Hotel Trust同比增速更快（7.9% vs -5.9%），Pebblebrook Hotel Trust自由现金流更多（$114.5M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -6.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Pebblebrook Hotel Trust是一家公开上市的房地产投资信托，主要在美国核心城市及休闲目的地持有、运营并投资高端、奢华及精品酒店物业，服务商务与休闲旅客，聚焦高需求市场以推动长期价值增长。
APLS vs PEB — 直观对比
营收规模更大
PEB
是对方的1.7倍
$199.9M
营收增速更快
PEB
高出13.9%
-5.9%
净利率更高
PEB
高出24.2%
-29.5%
自由现金流更多
PEB
多$128.8M
$-14.3M
两年增速更快
APLS
近两年复合增速
-6.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $345.7M |
| 净利润 | $-59.0M | $-18.4M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 2.3% |
| 净利率 | -29.5% | -5.3% |
| 营收同比 | -5.9% | 7.9% |
| 净利润同比 | -62.2% | 31.8% |
| 每股收益（稀释后） | $-0.40 | $-0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSPEB
| Q1 26 | — | $345.7M | ||
| Q4 25 | $199.9M | $349.0M | ||
| Q3 25 | $458.6M | $398.7M | ||
| Q2 25 | $178.5M | $407.5M | ||
| Q1 25 | $166.8M | $320.3M | ||
| Q4 24 | $212.5M | $337.6M | ||
| Q3 24 | $196.8M | $404.5M | ||
| Q2 24 | $199.7M | $397.1M |
净利润APLSPEB
| Q1 26 | — | $-18.4M | ||
| Q4 25 | $-59.0M | $-17.9M | ||
| Q3 25 | $215.7M | $-33.1M | ||
| Q2 25 | $-42.2M | $18.1M | ||
| Q1 25 | $-92.2M | $-32.9M | ||
| Q4 24 | $-36.4M | $-50.5M | ||
| Q3 24 | $-57.4M | $43.7M | ||
| Q2 24 | $-37.7M | $30.9M |
营业利润率APLSPEB
| Q1 26 | — | 2.3% | ||
| Q4 25 | -25.6% | 2.5% | ||
| Q3 25 | 48.7% | -2.6% | ||
| Q2 25 | -18.6% | 12.9% | ||
| Q1 25 | -50.0% | -2.3% | ||
| Q4 24 | -12.3% | -6.7% | ||
| Q3 24 | -24.0% | 11.6% | ||
| Q2 24 | -14.7% | 15.4% |
净利率APLSPEB
| Q1 26 | — | -5.3% | ||
| Q4 25 | -29.5% | -5.1% | ||
| Q3 25 | 47.0% | -8.3% | ||
| Q2 25 | -23.6% | 4.4% | ||
| Q1 25 | -55.3% | -10.3% | ||
| Q4 24 | -17.1% | -15.0% | ||
| Q3 24 | -29.2% | 10.8% | ||
| Q2 24 | -18.9% | 7.8% |
每股收益（稀释后）APLSPEB
| Q1 26 | — | $-0.26 | ||
| Q4 25 | $-0.40 | $-0.22 | ||
| Q3 25 | $1.67 | $-0.37 | ||
| Q2 25 | $-0.33 | $0.06 | ||
| Q1 25 | $-0.74 | $-0.37 | ||
| Q4 24 | $-0.30 | $-0.47 | ||
| Q3 24 | $-0.46 | $0.24 | ||
| Q2 24 | $-0.30 | $0.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $196.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $2.4B |
| 总资产 | $1.1B | $5.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSPEB
| Q1 26 | — | $196.2M | ||
| Q4 25 | $466.2M | $184.2M | ||
| Q3 25 | $479.2M | $223.2M | ||
| Q2 25 | $370.0M | $256.1M | ||
| Q1 25 | $358.4M | $208.1M | ||
| Q4 24 | $411.3M | $206.7M | ||
| Q3 24 | $396.9M | $134.0M | ||
| Q2 24 | $360.1M | $101.7M |
总债务APLSPEB
| Q1 26 | — | — | ||
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $2.2B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B |
股东权益APLSPEB
| Q1 26 | — | $2.4B | ||
| Q4 25 | $370.1M | $2.5B | ||
| Q3 25 | $401.2M | $2.5B | ||
| Q2 25 | $156.3M | $2.6B | ||
| Q1 25 | $164.2M | $2.6B | ||
| Q4 24 | $228.5M | $2.7B | ||
| Q3 24 | $237.1M | $2.8B | ||
| Q2 24 | $264.3M | $2.7B |
总资产APLSPEB
| Q1 26 | — | $5.3B | ||
| Q4 25 | $1.1B | $5.3B | ||
| Q3 25 | $1.1B | $5.6B | ||
| Q2 25 | $821.4M | $5.7B | ||
| Q1 25 | $807.3M | $5.7B | ||
| Q4 24 | $885.1M | $5.7B | ||
| Q3 24 | $901.9M | $5.7B | ||
| Q2 24 | $904.5M | $5.7B |
负债/权益比APLSPEB
| Q1 26 | — | — | ||
| Q4 25 | — | 0.86× | ||
| Q3 25 | — | 0.89× | ||
| Q2 25 | — | 0.85× | ||
| Q1 25 | — | 0.85× | ||
| Q4 24 | — | 0.83× | ||
| Q3 24 | — | 0.80× | ||
| Q2 24 | — | 0.80× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $114.5M |
| 自由现金流率自由现金流/营收 | -7.1% | 33.1% |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSPEB
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $249.7M | ||
| Q3 25 | $108.5M | $77.6M | ||
| Q2 25 | $4.4M | $90.5M | ||
| Q1 25 | $-53.4M | $50.3M | ||
| Q4 24 | $19.4M | $275.0M | ||
| Q3 24 | $34.1M | $76.1M | ||
| Q2 24 | $-8.3M | $83.7M |
自由现金流APLSPEB
| Q1 26 | — | $114.5M | ||
| Q4 25 | $-14.3M | $152.3M | ||
| Q3 25 | $108.3M | $6.8M | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | $146.3M | ||
| Q3 24 | — | $-24.8M | ||
| Q2 24 | $-8.4M | — |
自由现金流率APLSPEB
| Q1 26 | — | 33.1% | ||
| Q4 25 | -7.1% | 43.6% | ||
| Q3 25 | 23.6% | 1.7% | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | 43.3% | ||
| Q3 24 | — | -6.1% | ||
| Q2 24 | -4.2% | — |
资本支出强度APLSPEB
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 27.9% | ||
| Q3 25 | 0.0% | 17.7% | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | 38.1% | ||
| Q3 24 | 0.0% | 24.9% | ||
| Q2 24 | 0.0% | — |
现金转化率APLSPEB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | 5.01× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.74× | ||
| Q2 24 | — | 2.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
PEB
| Room | $214.5M | 62% |
| Food and beverage | $91.1M | 26% |
| Other | $40.0M | 12% |
